Tag Archives: Chris Shibutani

Cowen & Co. Keeps a Buy Rating on G1 Therapeutics Inc (GTHX)

In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on G1 Therapeutics Inc (GTHX – Research Report). The company’s shares opened today at $23.75. According to TipRanks.com, Shibutani is a 4-star analyst with an

Cowen & Co. Maintains a Buy Rating on Kura Oncology (KURA)

Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Kura Oncology (KURA – Research Report) today. The company’s shares opened today at $18.91. According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 2.0% and

Cowen & Co. Believes Array Biopharma (NASDAQ: ARRY) Won’t Stop Here

In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Array Biopharma (ARRY – Research Report), with a price target of $25. The company’s shares opened today at $47.04, close to its 52-week high

Analysts Offer Insights on Healthcare Companies: Esperion (NASDAQ: ESPR) and Kezar Life Sciences Inc (NASDAQ: KZR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Esperion (ESPR – Research Report) and Kezar Life Sciences Inc (KZR – Research Report) with bullish sentiments. Esperion (ESPR) In a report

Cowen & Co. Believes Mirati Therapeutics (NASDAQ: MRTX) Won’t Stop Here

Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Mirati Therapeutics (MRTX – Research Report) today. The company’s shares closed yesterday at $89.20, close to its 52-week high of $96.70. According to TipRanks.com, Shibutani is a 3-star analyst

Cowen & Co. Thinks Five Prime Therapeutics’ Stock is Going to Recover

In a report released yesterday, Chris Shibutani from Cowen & Co. maintained a Buy rating on Five Prime Therapeutics (FPRX – Research Report). The company’s shares closed on Friday at $8.40, close to its 52-week low of $7.84. According to